Barriers to treatment of hepatitis C in HIV/HCV coinfected adults in Brazil

Página do item simplificado
dc.contributor.authorMendes-Correa, Maria Cassia
dc.contributor.authorMartins, Lisia Gomes
dc.contributor.authorTenore, Simone de Barros [UNIFESP]
dc.contributor.authorLeite, Olavo Henrique Munhoz
dc.contributor.authorLeite, Andréa Gurgel Batista
dc.contributor.authorCavalcante, A. J. W.
dc.contributor.authorShimose, Mitsue
dc.contributor.authorSilva, Mariliza Henrique da
dc.contributor.authorUip, David Everson
dc.contributor.institutionFac Med ABC
dc.contributor.institutionAIDS Outpatient Clin
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:59:37Z
dc.date.available2016-01-24T13:59:37Z
dc.date.issued2010-05-01
dc.description.abstractThe objective of this study was to assess the prevalence of barriers to interferon treatment in a population of HIV/HCV coinfected patients. A cross-sectional study was conducted at two AIDS Outpatient Clinics in Brazil. the study included all HIV infected patients followed at these institutions from January 2005 to November 2007. Medical records of 2,024 HIV-infected patients were evaluated. the prevalence of anti-HCV positive patients among them was 16.7%. Medical records of HCV/HIV coinfected patients were analyzed. 189 patients with the following characteristics were included in our study: mean age 43 years; male gender 65%; former IDUs (52%); HCV genotype 1 (66.4%); HCV genotype 3 (30.5%); median CD4+ T cell count was 340 cells/mm(3). Among 189 patients included in the analyses, only 75 (39.6%) were considered eligible for HCV treatment. the most frequent reasons for non-treatment were: non-compliance during clinical follow-up (31.4%), advanced HIV disease (21.9%), excessive alcohol consumption or active drug use (18.7%), and psychiatric disorders (10.1%). Conclusions: in Brazil, as in elsewhere, more than half of HIV/HCV coinfected patients (60.4%) have been considered not candidates to received anti-HCV treatment. the main reasons may be deemed questionable: non-adherence, drug abuse, and psychiatric disease. Our results highlight the importance of multidisciplinary teams to optimize the access of coinfected patients to HCV treatment.en
dc.description.affiliationFac Med ABC, Infect Dis Res Unit, São Paulo, Brazil
dc.description.affiliationAIDS Outpatient Clin, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, AIDS Outpatient Clin, Fac Med, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, AIDS Outpatient Clin, Fac Med, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent237-241
dc.identifierhttps://dx.doi.org/10.1590/S1413-86702010000300007
dc.identifier.citationBrazilian Journal of Infectious Diseases. Salvador: Contexto, v. 14, n. 3, p. 237-241, 2010.
dc.identifier.doi10.1590/S1413-86702010000300007
dc.identifier.issn1413-8670
dc.identifier.scieloS1413-86702010000300007
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/32495
dc.identifier.wosWOS:000281693400007
dc.language.isoeng
dc.publisherContexto
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHepatitis Cen
dc.subjectHIVen
dc.subjectCoinfecteden
dc.subjectTreatmenten
dc.titleBarriers to treatment of hepatitis C in HIV/HCV coinfected adults in Brazilen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos